Engineering PEG10-assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination
eLife · 2024
DOI: 10.7554/elife.98579 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Ruijing Tang und 10 weiteren Autor:innen. Beteiligte Einrichtung: The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical Unive…. Hauptthemen laut MEDLINE: Cancer Vaccines, Antigens, Neoplasm, Dendritic Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Natural Science Foundation of China, The Major Research Projects for Young and Middle-aged Talent of Fujian Provincial Health Commission, The Young and Middle-aged Talent of Fujian Provincial Health Commission.
Abstract (Originalsprache)
Tumor neoantigen peptide vaccines hold potential for boosting cancer immunotherapy, yet efficiently co-delivering peptides and adjuvants to antigen-presenting cells in vivo remains challenging. Virus-like particle (VLP), which is a kind of multiprotein structure organized as virus, can deliver therapeutic substances into cells and stimulate immune response. However, the weak targeted delivery of VLP in vivo and its susceptibility to neutralization by antibodies hinder their clinical applications. Here, we first designed a novel protein carrier using the mammalian-derived capsid protein PEG10, which can self-assemble into endogenous VLP (eVLP) with high protein loading and transfection efficiency. Then, an engineered tumor vaccine, named ePAC, was developed by packaging genetically encoded neoantigen into eVLP with further modification of CpG-ODN on its surface to serve as an adjuvant and targeting unit to dendritic cells (DCs). Significantly, ePAC can efficiently target and transport neoantigens to DCs, and promote DCs maturation to induce neoantigen-specific T cells. Moreover, in mouse orthotopic liver cancer and humanized mouse tumor models, ePAC combined with anti-TIM-3 exhibited remarkable antitumor efficacy. Overall, these results support that ePAC could be safely utilized as cancer vaccines for antitumor therapy, showing significant potential for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
- The Liver Center of Fujian Province, Fujian Medical University, Shanghai, China.
- Mengchao Med-X Center, Fuzhou University, Fuzhou, China.
- State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
ORCID-Profile: Huan Yang, Zhixiong Cai, Xiaolong Liu
Förderung
- The National Natural Science Foundation of China
- The Major Research Projects for Young and Middle-aged Talent of Fujian Provincial Health Commission
- The Young and Middle-aged Talent of Fujian Provincial Health Commission
- The Scientific Foundation of Fujian Province
- Fujian Medical University
Zitieren
APA
Tang, R., Guo, L., Wei, T., Chen, T., Yang, H., Ye, H., Lin, F., Zeng, Y., Yu, H., Cai, Z., & Liu, X. (2024). Engineering PEG10-assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination. eLife. https://doi.org/10.7554/elife.98579
Vancouver
Tang R, Guo L, Wei T, Chen T, Yang H, Ye H, et al. Engineering PEG10-assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination. eLife. 2024. doi:10.7554/elife.98579
BibTeX
@article{Tang2024,
author = {Tang, Ruijing and Guo, Luobin and Wei, Tingyu and Chen, Tingting and Yang, Huan and Ye, Honghao and Lin, Fangzhou and Zeng, Yongyi and Yu, Haijun and Cai, Zhixiong and Liu, Xiaolong},
title = {Engineering PEG10-assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.98579}
}
EUVIMED